Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2041210004
JPRN-jRCT2041210004Active, not recruitingPhase 3

Phase III clinical trial of favipiravir in early-onset COVID-19 patients with severe risk factors-Placebo-controlled, stratified Randomized, Multicenter, Double-blind study

Sakurai Tsutomu0 sites316 target enrollmentStarted: April 14, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Status
Active, not recruiting
Sponsor
Enrollment
316
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • •1.Patients with positive SARS-CoV-2 test result by RT-PCR or loop-mediated isothermal amplification (LAMP) method or antigen test.
  • •2.Patient within 72 hours from onset of first COVID-19 symptom
  • •3.Patients with risk factors of progression to severe disease
  • •4.Have a negative pregnancy test before study treatment
  • •5.Patients can obtain written informed consent from the patients.

Exclusion Criteria

  • •1.Patients receiving oxygen therapy prior to the start of study treatment.
  • •2.Patients with any of COVID-19 clinical symptoms/findings of dyspnea or a respiratory rate of 30 breaths/min or more.
  • •3.Patients with SARS-CoV-2 vaccinated

Investigators

Sponsor
Sakurai Tsutomu

Similar Trials

Completed
Phase 3
Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia SyndromeSevere Fever with Thrombocytopenia Syndrome (SFTS)
JPRN-jRCT2080223816FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)30
Completed
Phase 3
Efficacy and Safety of Favipiravir in Management of COVID-19Coronavirus Disease (COVID-19)
NCT04349241Ain Shams University100
Active, not recruiting
Phase 1
A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravirHIV-1 infectionMedDRA version: 20.1Level: LLTClassification code: 10068341Term: HIV-1 infection Class: 10021881
CTIS2022-502126-40-00Merck Sharp & Dohme LLC1,312
Active, not recruiting
Phase 3
Follow-up of Participants Who Received DOR/ISL (100 mg/0.75 mg)HIV-1 Infection
JPRN-jRCT2051230002Tanaka Yoshiyuki1,300
Recruiting
Phase 3
The therapeutic effect of Favipiravir in COVID-19 patients
IRCT20211004052664N1Shahid Beheshti University of Medical Sciences80